Zoledronic acid (Zometa)

An FDA approved treatment for bone complications in patients with bone-metastatic cancer, including castrate resistant prostate cancer. Zoledronic acid belongs to a class of drugs called bisphosphonates, which slows the process of bone breakdown and reabsorbption.